Article Sidebar

pdf
Date Published: 15/05/2024
Abstract Views: 288
Views pdf: 135
DOI: https://doi.org/10.51298/vmj.v538i3.9566
Issue
Vol. 538 No. 3 (2024)
Section
Các bài báo
How to Cite
Trần, Đình A., & Nguyễn, Ái L. (2024). TREATMENT RESULTS OF FIRST-LINE AFATINIB FOR ADVANCED EGFR-MUTANT NON-SMALL CELL LUNG CANCER IN HANOI MEDICAL UNIVERSITY. Vietnam Medical Journal, 538(3). https://doi.org/10.51298/vmj.v538i3.9566

TREATMENT RESULTS OF FIRST-LINE AFATINIB FOR ADVANCED EGFR-MUTANT NON-SMALL CELL LUNG CANCER IN HANOI MEDICAL UNIVERSITY

Đình Anh Trần, Ái Linh Nguyễn

Main Article Content

Abstract

Objectives: Evaluating the result of afatinib in advanced-stage non-small cell lung cancer (IIIC, IV) in Hanoi Medical University.Patients and methods: Descriptive study of 34 patients with stage IIIC, IV NSCLC with EGFR mutations at Hanoi Medical University Hospital from 01/2018 to 6/2021. Results: the rate of Del19 and L585R mutations was 44.1% and 20.6%; stage IVB accounted for the highest rate (70%), 1 patient was diagnosed with a relapse. At the time of 8-12 weeks, the overall response rate reached 76.5%, the stable disease accounted for 20.6%, and only 2.9% of the disease progressed. Median progression-free survival (PFS) was 12.0 ± 3.1 months (5.9-18.0 months). There was no statistically significant difference in progression-free survival when analyzed with related factors such as gene mutation status, starting dose, adjusted dose, and optimal dose of afatinib. The most common toxicities were skin rash (35.3%), paronychia  (35.3%), and diarrhea (32.4%).

Article Details

Keywords

advanced Non-small cell lung cancer (NSCLC), EGFR mutation, afatinib.

References

1. Sung H, Ferlay J, Siegel RL (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
2. Thuan Tran Van APT, Tu Dao Van (2016). Cancer control in Vietnam: where are we now. Cancer Control, 2016, 99-104.
3. Planchard D, Popat S, Kerr K, et al (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 29, iv192-iv237.
4. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 21, 3798-807.
5. Mok TS, Wu Y-L, Thongprasert S, et al (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
6. Wu YL, Zhou C, Hu CP, et al (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 15, 213-22.
7. Sequist LV, Yang JC, Yamamoto N, et al (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 31, 3327-34.
8. Watanabe S, Minegishi Y, Yoshizawa H, et al (2014). Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol, 9, 189-94.
9. Yang JC, Sequist LV, Geater SL, et al (2015a). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX- Lung 6. Lancet Oncol, 16, 830-8.
10. Kim Y, Lee SH, Ahn JS, et al (2019). Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat, 51, 502-9.